GGrantIndex
← Leaderboards

Robert Coleman Lindsley

Dana-Farber Cancer Inst

$5,306,772
Attributed
$10,130,878
Total exposure
4
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.1M · FY201623
$2.5M$1.9M$1.3M$625K$0
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$10,130,878 · 4

By mechanism

RC2$6,432,141 · 1
P01$2,885,355 · 2
K08$813,382 · 1

Top collaborators

Most similar at Dana-Farber Cancer Inst

Same institution · by research overlap

Others in their field

Top investigators on “Biology

Research focus

BiologyCohortCellsHematopoiesisSamplingMutationTechnologyGeneticEpigenetic ProcessMyeloproliferative DiseaseTranscriptomicsTranscriptomeProductionClonal EvolutionHematopoietic Stem CellsHigh RiskHematopoieticInnovationLeukemiaDysmyelopoietic SyndromesGenesAcute Myelocytic LeukemiaAffectDisease Progression

Grant awards (15)

Systems Biology of Bone Marrow Failure and MDS for Precision Medicine$1,271,028
RC2 · FY2023 · DK
Defining the scope and clinical impact of donor CHIP after allogeneic HCT$568,893
P01 · FY2023 · CA · contact PI
Systems Biology of Bone Marrow Failure and MDS for Precision Medicine$1,271,028
RC2 · FY2022 · DK
Defining the scope and clinical impact of donor CHIP after allogeneic HCT$565,186
P01 · FY2022 · CA · contact PI
Systems Biology of Bone Marrow Failure and MDS for Precision Medicine$1,271,028
RC2 · FY2021 · DK
Defining the scope and clinical impact of donor CHIP after allogeneic HCT$576,720
P01 · FY2021 · CA · contact PI
Systems Biology of Bone Marrow Failure and MDS for Precision Medicine$1,278,845
RC2 · FY2020 · DK
Defining the scope and clinical impact of donor CHIP after allogeneic HCT$577,528
P01 · FY2020 · CA · contact PI
Determining the Role of BCOR Mutations in Myeloid Malignancies$141,236
K08 · FY2020 · CA · contact PI
Systems Biology of Bone Marrow Failure and MDS for Precision Medicine$1,340,212
RC2 · FY2019 · DK
Defining the scope and clinical impact of donor CHIP after allogeneic HCT$597,028
P01 · FY2019 · CA · contact PI
Determining the Role of BCOR Mutations in Myeloid Malignancies$141,236
K08 · FY2019 · CA · contact PI
Determining the Role of BCOR Mutations in Myeloid Malignancies$176,970
K08 · FY2018 · CA · contact PI
Determining the Role of BCOR Mutations in Myeloid Malignancies$176,970
K08 · FY2017 · CA · contact PI
Determining the Role of BCOR Mutations in Myeloid Malignancies$176,970
K08 · FY2016 · CA · contact PI